home / stock / bvaxf / bvaxf news

BVAXF News and Press, BioVaxys Technology Corp.

Stock Information
Company Name: BioVaxys Technology Corp.
Stock Symbol: BVAXF
Market: OTC
Website: biovaxys.com
Menu
BVAXF BVAXF Quote BVAXF Short BVAXF News BVAXF Articles BVAXF Message Board
Get BVAXF Alerts

News, Short Squeeze, Breakout and More Instantly...
BVAXF - BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

(TheNewswire)   Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer   VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) (“BioVaxys" or the "Company"), a c...
BVAXF - BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Study subject Remains in Complete Response for 3 Years Exceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent Chemotherapy Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB...

BVAXF - BioVaxys 1Q2026 R&D and Collaborative Activity

(TheNewswire)   VANCOUVER, BC, January 15 th ,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to provide an update on 1Q2026 initiatives, including collaborations and non-dilutive funding programs. Th...

BVAXF - BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other im...
BVAXF - 2025 Corporate Review

(TheNewswire) VANCOUVER, BC, December 31 st . 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating initiatives over the past year following the integration of the DPX™ platform i...

BVAXF - Phase 1 Results Drive New Attention to Breast Cancer Play

2025-12-17 10:03:00 ET Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outc...

BVAXF - BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other i...
BVAXF - BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

(TheNewswire) VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford was V...

BVAXF - BioVaxys Technology Corp. Closes Debt Settlement Transaction

(TheNewswire) VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announces that, further to its news release dated November 14, 2025, it has issued 1,7...

BVAXF - BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

2025-11-19 10:02:35 ET VANCOUVER, BC, November 19, 2025 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Offering&#x...
Next 10